PHIBRO ANIMAL HEALTH CORP

Listed Company

PAHCCIK 0001069899NasdaqAcceleratedPharmaceutical PreparationsDelawareFY ends Jun 30

Period

FY 2025

Revenue

$1.30B

Net Income

$48.26M

Total Assets

$1.36B

Equity

$285.68M

Shares Out

68.91M

Op. Cash Flow

$80.12M

Business

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company that provides solutions to maintain and enhance the health of farm and companion animals. It develops, manufactures and markets approximately 800 product lines, including antibacterials, anticoccidials, nutritional specialty products, vaccines and vaccine adjuvants, trace mineral formulations and specialty performance ingredients. The company manages three business segments—Animal Health, Mineral Nutrition and Performance Products—each with dedicated management and sales teams. It distributes products in about 90 countries to livestock producers, feed manufacturers, wholesalers, distributors, veterinarians and industrial customers through direct sales and distributor networks.

Summary from filing dated 2025-08-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Net sales	1,296	1,018	978	942	833
Cost of goods sold	−896	−705	−680	657	562
Gross profit	400	313	298	285	271
Selling, general and administrative expenses	289	260	226	206	197
Operating income	110	53	72	79	75
Interest expense, net	35	19	15	12	—
Foreign currency losses, net	8	24	2	−5	−4
Income before income taxes	68	11	54	72	66
Provision for income taxes	20	9	21	23	12
Net income	48	2	33	49	54
basic (in dollars per share)	1.19	0.06	0.81	1.21	1.34
diluted (in dollars per share)	1.19	0.06	0.81	1.21	1.34
basic (in shares)	41	41	41	41	40
diluted (in shares)	41	41	41	41	41

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Cash and cash equivalents	68	71	41	74	50
Short-term investments	9	44	40	17	43
Accounts receivable, net	228	169	163	167	147
Inventories, net	444	266	278	259	216
Other current assets	61	51	63	49	43
Total current assets	811	601	586	566	499
Property, plant and equipment, net	355	203	196	165	155
Intangibles, net	36	45	55	64	62
Goodwill	60	55	53	53	53
Other assets	99	78	82	83	73
Total assets	1,361	982	971	932	841
Current portion of long-term debt	16	30	22	15	9
Accounts payable	138	86	74	96	68
Accrued expenses and other current liabilities	139	89	80	80	86
Total current liabilities	293	204	176	191	164
Revolving credit facility	87	176	141	145	95
Long-term debt	615	282	312	273	288
Other liabilities	79	63	60	61	56
Total liabilities	1,075	726	689	669	603
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,367,574 shares issued and outstanding at June 30, 2025, and 20,337,574 shares issued and outstanding at June 30, 2024; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at June 30, 2025, and June 30, 2024	4,000	4,000	4,000	4,000	4,000
Paid-in capital	137	136	136	136	136
Retained earnings	273	244	261	248	218
Accumulated other comprehensive loss	−124	−124	−114	−121	−115
Total stockholders' equity	286	257	283	262	239
Total liabilities and stockholders' equity	1,361	982	971	932	841

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Net income	48	2	33	49	54
Depreciation and amortization	46	36	34	33	32
Amortization of debt issuance costs	2	1	727,000	590,000	833,000
Deferred income taxes	−5	−12	−3	−806,000	−2
Foreign currency losses (gains), net	600,000	13	−10	−5	−10
Acquisition-related items	6	521,000	—	316,000	—
Non-cash impairment charges	5	—	—	—	—
Pension settlement cost	—	11	—	—	—
Brazil employment taxes	—	4	—	—	—
Stock-based compensation expense	717,000	475,000	—	—	1
Other	−2	−2	334,000	319,000	2
Accounts receivable, net	−55	−9	5	−24	−18
Inventories, net	−44	3	−11	−47	−12
Other current assets	−16	11	−7	−2	−2
Other assets	2	4	750,000	−2	−2
Accounts payable	46	12	−23	26	3
Accrued expenses and other liabilities	47	12	−6	3	1
Net cash provided by operating activities	80	88	13	32	48
Purchases of short-term investments	−14	−66	−40	−64	−74
Maturities of short-term investments	49	62	17	90	86
Capital expenditures	−38	−41	−52	−37	−29
Business acquisition, net of cash acquired	−287	−3	—	−14	—
Other, net	1	326,000	776,000	620,000	−1
Net cash used by investing activities	−289	−48	−74	−23	−19
Revolving credit facility borrowings	532	276	264	297	318
Revolving credit facility repayments	−621	−241	−268	−247	−392
Proceeds from long-term debt	650	—	62	—	300
Payments of long-term debt	−325	−22	−15	−9	−221
Debt issuance costs	−10	—	−1	—	−3
Proceeds from insurance premium financing and other short-term debt	8	9	6	—	—
Payments of insurance premium financing and other short-term debt	−7	−9	−1	—	—
Dividends paid	−19	−19	−19	−19	−19
Net cash provided (used) by financing activities	207	−7	27	16	−17
Effect of exchange rate changes on cash	−1	−3	754,000	−1	1
Net (decrease) increase in cash and cash equivalents	−3	29	−33	24	14
Interest paid, net	32	17	15	11	11
Income taxes paid, net	13	15	20	18	19
Property, plant and equipment	7	2	3	3	3

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro